President Trump is planning to sign an executive order to research the use of a psychedelic drug in the treatment of post-traumatic stress disorder (PTSD), according to a new report.
CBS News detailed that the order is in the works and would have the government look into and research the viability of using the drug ibogaine in treatment.
The network added that the drug has been used to treat depression, anxiety, addictions, PTSD, and brain trauma, but is illegal in the U.S. Some studies have shown the drug can have severe health side effects.
According to Stanford Medicine, ibogaine is a naturally occurring, plant-based psychoactive compound. In 2025, Stanford Medicine researchers published a study in Nature Mental Health, which found that when combined with magnesium to protect the heart, it could safely and effectively reduce PTSD, anxiety, and depression. The study also argued that it could help improve functioning in veterans with traumatic brain injuries.
The study was limited in scope and only involved 30 individuals.
A review of 23 studies by the Journal of Substance Abuse and Addiction Treatment found that "ibogaine is an effective therapeutic intervention...reducing withdrawal symptoms and craving. Data also point toward a beneficial impact on depressive and trauma-related psychological symptoms."
But the studies also reported a variety of potential health risks. "Studies have reported severe medical complications and deaths, which seem to be associated with neuro- and cardiotoxic effects of ibogaine," the JSAT report states.
CBS News reported that Trump's order will not reclassify the drug for medical use but will clear the way for funding for further research into its efficacy and safety.
